Vera Therapeutics, Inc. — Director's Dealing 2021

May 14, 2021

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Vera Therapeutics, Inc. (VERA)
CIK: 0001831828
Period of Report: 2021-05-13

Reporting Person: Ares Trading S.A. (10% Owner)
Reporting Person: Merck KGaA (10% Owner)
Reporting Person: MERCK SERONO S.A. (10% Owner)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Series C Preferred Stock	$		Class A Common Stock (1913501)		Direct

Footnotes

F1: The Series C Preferred Stock is convertible into Class A Common Stock on a 11.5869:1 basis (on an adjusted basis, after giving effect to the reverse stock split of the Class A Common Stock effected by the Issuer on May 7, 2021) and has no expiration date. Upon filing of the Issuer's Restated Certificate of Incorporation in connection with the Issuer's initial public offering, all shares of Series C Preferred Stock will be converted into shares of Class A Common Stock of the Issuer.